|Bid||85.10 x 500|
|Ask||85.40 x 400|
|Day's range||84.95 - 87.69|
|52-week range||84.95 - 147.17|
|PE ratio (TTM)||23.35|
|Earnings date||25 Apr 2018 - 30 Apr 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||117.27|
A German biotech with the potential to rival Gilead, Novartis and Celgene in cancer drugs is looking to file an IPO in the U.S.
Blockbuster arthritis treatment Humira helped build AbbVie Inc. into a pharmaceutical-industry behemoth. Now investors are growing concerned about the drugmaker’s second act.
The biotech sector was in focus last week with Alexion gaining on positive data on PNH candidate, Arena surges on ulcerative drug data, Solid Biosciences' stock suffering a crash and Prothena teaming up with Celgene.
Shares of Prothena (PRTA) surged significantly after the company announced a multi-year collaboration with leading company Celgene to develop new therapies for a broad range of neurodegenerative diseases.
Prothena jumped by doubt digits late Tuesday on a $150 million deal with Celgene to develop treatments for neurodegenerative diseases.
Prothena Corp. shares rallied in the extended session Tuesday after the biotech company said Celgene Corp. was investing and partnering with the company on treatments for neurodegenerative diseases. Prothena ...
On a day most indexes made gains, Arena Pharmaceuticals skyrocketed following drug trial results and Duluth Holdings fell on a weak forecast for 2018 sales.
Arena gapped up by nearly a third Tuesday after its ulcerative colitis drug proved strong in a Phase 2 trial.
Prothena to receive a $100 million upfront payment and a $50 million equity investment by Celgene, with potential license payments and regulatory and commercial milestones, plus additional royalties on ...
The healthcare sector bounced back in 2017 and has performed in line with the S&P 500 so far in 2018. Here’s a look at what’s been going on in the sector ahead of first-quarter earnings.
Amgen would be better off stringing together small deals, rather than attempting a megamerger, an analyst suggested Monday.
Whether you're a liberal fan of MSNBC or a conservative viewer of Fox, there is no escaping ads for psoriasis treatments.